Novartis is a renowned
multinational business that deals in the research and development of products
aimed at establishing safe healthcare. It was established in 1996 as a result
of the merger of two prestigious companies; Ciba-Geigy and Sandoz. Novartis is
present in nearly 140 countries all over the world where it is engaged in
numerous activities such as the provision of Vaccines, generics,
pharmaceuticals and eye care. It operates with the aim of improvement of life
quality over the globe.
In accordance with this
aim, Novartis had developed a new Lucentis drug that was intended to enhance
eyesight and reduce vision loss. Results have shown that the effects of the
drug in reducing eyesight loss can already be seen across many indicators. This
success has profoundly soared the company’s popularity. It can also be felt in
the stock markets as activity has increased following the proved effectiveness
of the medicine, NVS shares rose by
1%. The Swiss stock market was also showing a bullish trend mostly due to the
brilliant financial performance exhibited by Novartis and Nestle.
The impact of this
development are also apparent in the analysis of NVS stock charts and stock prices. The stock charts have been on the rise following the development. The stock price today is $88.41. It has
risen as compared to the same time last year when it was 73.65. This shows that the higher profitability
which accompanied the development of the drug has been welcomed by investors.
No comments:
Post a Comment